vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $182.4M, roughly 1.5× Climb Global Solutions, Inc.). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs -45.7%, a 47.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 32.1%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 29.2%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CLMB vs GH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $281.3M |
| Net Profit | $3.3M | $-128.5M |
| Gross Margin | 14.5% | 64.6% |
| Operating Margin | 2.1% | -43.0% |
| Net Margin | 1.8% | -45.7% |
| Revenue YoY | 32.1% | 39.4% |
| Net Profit YoY | -9.5% | -15.8% |
| EPS (diluted) | $0.18 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $281.3M | ||
| Q3 25 | $161.3M | $265.2M | ||
| Q2 25 | $159.3M | $232.1M | ||
| Q1 25 | $138.0M | $203.5M | ||
| Q4 24 | $161.8M | $201.8M | ||
| Q3 24 | $119.3M | $191.5M | ||
| Q2 24 | $92.1M | $177.2M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $-128.5M | ||
| Q3 25 | $4.7M | $-92.7M | ||
| Q2 25 | $6.0M | $-99.9M | ||
| Q1 25 | $3.7M | $-95.2M | ||
| Q4 24 | $7.0M | $-111.0M | ||
| Q3 24 | $5.5M | $-107.8M | ||
| Q2 24 | $3.4M | $-102.6M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 64.6% | ||
| Q3 25 | 15.9% | 64.7% | ||
| Q2 25 | 16.5% | 65.0% | ||
| Q1 25 | 16.9% | 63.3% | ||
| Q4 24 | 19.3% | 61.6% | ||
| Q3 24 | 20.3% | 61.1% | ||
| Q2 24 | 20.2% | 59.1% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | -43.0% | ||
| Q3 25 | 4.3% | -37.3% | ||
| Q2 25 | 5.0% | -45.9% | ||
| Q1 25 | 3.5% | -54.6% | ||
| Q4 24 | 7.2% | -62.4% | ||
| Q3 24 | 7.1% | -61.3% | ||
| Q2 24 | 4.6% | -56.8% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | -45.7% | ||
| Q3 25 | 2.9% | -35.0% | ||
| Q2 25 | 3.7% | -43.0% | ||
| Q1 25 | 2.7% | -46.8% | ||
| Q4 24 | 4.3% | -55.0% | ||
| Q3 24 | 4.6% | -56.3% | ||
| Q2 24 | 3.7% | -57.9% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $-1.01 | ||
| Q3 25 | $1.02 | $-0.74 | ||
| Q2 25 | $1.30 | $-0.80 | ||
| Q1 25 | $0.81 | $-0.77 | ||
| Q4 24 | $1.52 | $-0.90 | ||
| Q3 24 | $1.19 | $-0.88 | ||
| Q2 24 | $0.75 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $118.4M | $-99.3M |
| Total Assets | $458.8M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $378.2M | ||
| Q3 25 | $49.8M | $580.0M | ||
| Q2 25 | $28.6M | $629.1M | ||
| Q1 25 | $32.5M | $698.6M | ||
| Q4 24 | $29.8M | $525.5M | ||
| Q3 24 | $22.1M | $585.0M | ||
| Q2 24 | $48.4M | $933.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $-99.3M | ||
| Q3 25 | $109.3M | $-354.5M | ||
| Q2 25 | $105.2M | $-305.5M | ||
| Q1 25 | $95.6M | $-250.8M | ||
| Q4 24 | $90.6M | $-139.6M | ||
| Q3 24 | $87.7M | $-60.1M | ||
| Q2 24 | $79.8M | $-1.6M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $2.0B | ||
| Q3 25 | $376.1M | $1.3B | ||
| Q2 25 | $420.7M | $1.3B | ||
| Q1 25 | $370.1M | $1.3B | ||
| Q4 24 | $469.2M | $1.5B | ||
| Q3 24 | $371.9M | $1.5B | ||
| Q2 24 | $302.8M | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $-26.4M | ||
| Q3 25 | $22.2M | $-35.4M | ||
| Q2 25 | $-2.2M | $-60.3M | ||
| Q1 25 | $8.5M | $-62.7M | ||
| Q4 24 | $16.0M | $-64.5M | ||
| Q3 24 | $-3.6M | $-51.1M | ||
| Q2 24 | $7.3M | $-94.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
